SARS-CoV2 drives JAK1/2-dependent local and systemic complement hyper-activation

Biochemistry, Genetics and Molecular Biology

• Drive 100%
• Coronavirinae 100%
• STAT1 33%
• Gene Signature 33%
• Angiotensin-Converting Enzyme 2 33%
• Complement System 33%
• Interferon Type I 33%
• SARS Coronavirus 33%
• Myeloid 33%
• Interleukin 6 33%
• Interferon 33%
• Janus Kinase Inhibitor 33%
• Ruxolitinib 33%
• Complement Activation 33%

Immunology and Microbiology

• Severe Acute Respiratory Syndrome 100%
• COVID-19 100%
• Interferon Type I 66%
• Complement System 33%
• Myeloid 33%
• STAT1 33%
• Interleukin 6 33%
• Liver Cell 33%
• Angiotensin 33%
• Complement Activation 33%
• SARS Coronavirus 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Diseases 100%
• Severe Acute Respiratory Syndrome 100%
• Coronavirinae 60%
• Disease Severity 20%
• Receptor 20%
• Infection 20%
• Combination Therapy 20%
• Interleukin 6 20%
• Antivirus Agent 20%
• Janus Kinase Inhibitor 20%
• SARS Coronavirus 20%
• Interferon 20%
• Ruxolitinib 20%
• Angiotensin Converting Enzyme 2 20%
• Interferon Receptor 20%